Structure-activity relationship of quaternary acetylcholinesterase inhibitors - outlook for early Myasthenia gravis treatment

Current Medicinal Chemistry

Volumn 17, Issue 17, 2010, Pages 1810-1824

  Komloova, M ^a   Musilek, K ^b,d   Dolezal, M ^a   Gunn Moore, F ^e   Kuca, K ^b,c,d  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

^d J E PURKINJE UNIVERSITY   (Czech Republic)

^e UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Acetylcholinesterase; IC50; Inhibitor; Myasthenia gravis; Quaternary

Indexed keywords

1,1' TRIMETHYLENEBIS(4 HYDROXYIMINOMETHYLPYRIDINIUM) DIBROMIDE 2,6 DICHLOROBENZYL ETHER; 1,5 BIS(4 ALLYLDIMETHYLAMMONIUMPHENYL)PENTAN 3 ONE DIBROMIDE; AMBENONIUM; APORPHINE DERIVATIVE; AZATHIOPRINE; BENZOTHIOPHENE DERIVATIVE; BENZYLPIPERIDINIUM QUATERNARY SALT; BISQUATERNARY PYRIDINIUM SALT; CARBAMIC ACID ESTER; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DUO 3; EDROPHONIUM; GALANTAMINE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; NITROFURAN DERIVATIVE; NORGALANTAMINE; PIPERIDINE DERIVATIVE; PYRIDINIUM DERIVATIVE; PYRIDOSTIGMINE; QUATERNARY AMMONIUM DERIVATIVE; SANGUININE; TETRAHYDROPYRAN DERIVATIVE; TRIMEDOXIME; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CLINICAL FEATURE; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC 50; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ACETYLCHOLINESTERASE; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; HUMANS; MYASTHENIA GRAVIS; QUATERNARY AMMONIUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953495677     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791111198     Document Type: Article

References (43)

1. Phillips, L.H. The epidemiology of Myasthenia gravis. Ann. N Y Acad. Sci., 2003, 998, 407-412.
2. Juel, V.C.; Massey, J.M. Myasthenia gravis. Orphanet J. Rare Dis., 2007, 2, 44-57.
3. Hill, M. The neuromuscular junction disorders. J. Neurol. Neurosurg. Psychiatry, 2003, 74, 32-37.
4. Thanvi, B.R.; Lo, T.C.N. Update on myasthenia gravis. Postgrad. Med. J., 2004, 80, 690-700.
5. Hoch, W.; McConville, J.; Helms, S.; Newsom-Davis, J. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med., 2001, 7, 365-368.
6. Miller, N.R. Walsh and Hoyt's Clinical Neuro-ophthalmology, Williams & Wilkins, Baltimore, 1985.
7. Vincent, A.; Palace, J.; Hilton-Jones D. Myasthenia gravis. Lancet, 2001, 357, 2122-2128.
8. Galdi, A.P. Diagnosis and Management of Muscle Disease, SP Medical and Scientific Books, New York, 1984.
9. Schroeder, S.A. Current Medical Diagnosis and Treatment, Norwald: Appleton and Lange: Connecticut, 1988.
10. Phillips, L.H.; Torner, J.C. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology, 1996, 47, 1233-1238.
11. Gupta, R. Toxicology of organophosphate & carbamate compounds, Elsevier Academic Press: Amsterdam, 2006.
12. Donaldson, D.H. The relationship of age to outcome in myasthenia gravis. Neurology, 1990, 40, 786-790.
13. Thomann, K.H.; Pandya, S. Myasthenia gravis: pathophysiology, diagnosis, differential diagnosis and management. Clin. Eye Vis. Care, 1995, 7, 3-13.
14. Garcia-Carrasco, M.; Escarcega, R.O.; Fuentes-Alexandro, S.; Riebeling, C.; Cervera, R. Therapeutic options in autoimmune myasthenia gravis. Autoimmun. Rev., 2007, 6, 373-378.
15. Sakurada, K.; Matsubara, K. Pralidoxime iodide (2-PAM) penetrates across the blood-brain barrier. Neurochem. Res., 2003, 28, 1401-1407.
16. Millard, C.B.; Broomfield, C.A. Anticholinesterases: Medical applications of neurochemical principles. J. Neurochem., 1995, 64, 1909-1918.
17. Stedman, E. Studies on the relationship between chemical constitution and physiological action. Biochem. J., 1926, 20, 719-734.
18. Aeschlimann, J.A.; Reinert M. The pharmacological action of some analogues of physostigmine. J. Pharmacol. Exp. Ther., 1931, 43, 413-444.
19. Stevens, J.R.; Beutel, R.H. Physostigmine substitutes. J. Am. Chem. Soc., 1941, 63, 308-311.
20. Haworth, R.D.; Lamberton, A.H.; Woodcock, D. Investigations on the influence of chemical constitution upon toxicity. Part 1. Compounds related to "Doryl". J. Chem. Soc., 1947, 176-182.
21. Urban R. Disubstituted carbamic acid esters of 3-hydroxy-1-alkylpyridinium salts, United States Patent Office (No. 670838), 1945.
22. Wuest, H.M.; Sakal, E.H. Some derivatives of 3-pyridol with parasympathomimetic properties. J. Am. Chem. Soc., 1951, 73, 1210-1216.
23. Millner, O.E.; Stanley, J.W.; Purcell, W.P. Synthesis and enzymic evaluation of pyridostigmine analogs used to probe the active sites of acetylcholinesterase and butyrylcholinesterase J. Med. Chem., 1974, 17, 13-18.
24. Kolvezen, M.J.; Metcalf, R.L.; Fukuto, T.R. Insecticide structure and activity, insecticidal activity of carbamate cholinesterase inhibitors. J. Agric. Food. Chem., 1954, 2, 864-870.
25. Skrinjaric-Spoljar, M.; Burger, N.; Lovric J. Inhibition of acetylcholinesterase by three new pyridinium compounds and their effect on phosponylation of the enzyme. J. Enzym. Inhib., 1999, 14, 331-341.
26. Clark, J.K; Cowley P.; Muir, A.W. Quaternary salts of E2020 analoguea as acetylcholinesterase inhibitors for the reversal of neuromuscular block. Bioorg. Med. Chem. Lett., 2002, 12, 2565-2568.
27. Kaur, J.; Zhang, M.Q. Molecular modelling and QSAR of reversible acetylcholinesterase inhibitors. Curr. Med. Chem., 2000, 7, 273-294.
28. Ellman, G.L.; Courtney, K.D.; Andres, V.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 1961, 7, 88-95.
29. Palin, R.; Clark, J.K.; Cowley P. Novel piperidinium and pyridinium agents as water-soluble acetylcholinesterase inhibitors for the reversal of neuromuscular blockade. Bioorg. Med. Chem. Lett., 2002, 12, 2569-2572.
30. Musilek, K.; Kuca, K.; Jun, D.; Dolezal, M. Progress in synthesis of new acetylcholinesterase reactivators during the period 1990-2004. Curr. Org. Chem., 2007, 11, 229-238.
31. Lorke, D.E.; Kalasz, H.; Petroianu, G.A.; Tekes, K. Entry of oximes into the brain: a review. Curr. Med. Chem., 2008, 15, 743-753.
32. Buschendorf, K.; Mohr, K.; Shekenburger, J. Comparison between the allosteric and the competitive action of a series of ligands at mACh-receptors. Naunyn-Schmiedebergs Arch. Pharmacol., 1990, 341, R80.
33. Heber, D.; Mohr, K.; Ohnesorge, H. Bispyridinium compounds as allosteric modulators of M2 cholinoceptors. Naunyn-Schmiedebergs Arch. Pharmacol., 1991, 343, R290.
34. Botero-Cid, M.H.; Holzgrabe, U.; Kostenis, J.E.; Mohr, K.; Tränkle C. Search for the pharmacophore of bispyridinium-type allosteric modulators of muscarinic receptors. J. Med. Chem., 1994, 37, 1439-1445.
35. Kapkova, P.; Stiefl, N.; Sürig, U.; Engels, B.; Baumann, K.; Holzgrabe, U. Synthesis, biological activity, and docking studies of new acetylcholinesterase inhibitors of the bispyridinium type. Arch. Pharm. Pharm. Med. Chem., 2003, 336, 523-540.
36. Kapkova, P.; Alptuzun, V.; Frey, P.; Erciyas, E.; Holzgrabe, U. Search for dual function inhibitors for Alzheimers disease: Synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their A fibril formation inhibition capacity. Bioorg. Med. Chem., 2006, 14, 472-478.
37. Mary, A.; Renko, D.Z.; Guillou, C.; Thal, C. Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. Bioorg. Med. Chem., 1998, 6, 1835-1850.
38. Leonetti, F.; Catto, M.; Nicolotti, O.; Pisani, L.; Cappa, A.; Stefanachi, A.; Carotti, A. Homo and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. Bioorg. Med. Chem., 2008, 16, 7450-7456.
39. Hodge, A.S.; Humphrey, D.R.; Rosenberry, T.L. Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol. Pharmacol., 1992, 41, 937-942.
40. Atack, J.R.; Yu, Q.S.; Soncrant, T.T.; Brossi, V.; Rapoport, S.I. Comparative inhibitory effects of various physostigmine analogs against acetyl and butyrylcholinesterases. J. Pharmacol. Exp. Ther., 1989, 249, 194-202.
41. Tang, H.; Ning, F.X.; Wei, Y.B.; Huang S.L. Derivatives of oxoisoaporphine alkaloids: a novel class of selective acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 3765-3768.
42. Musilek, K.; Komloova, M.; Zavadova, V.; Holas, O.; Hrabinova, M.; Pohanka, M.; Dohnal, V.; Nachon, F.; Dolezal, M.; Kuca, K.; Jung, Y.-S. Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage initial study for Myasthenia gravis implications. Bioorg. Med. Chem. Lett., 2010, 10.1016/j.bmcl.2010.01.034.
43. Lorke, D. E.; Hasan, M. Y.; Arafat, K.; Kuca, K.; Musilek, K.; Schmitt, A.; Petroianu, G. A. In vitro oxime protection of human red blood cell acetylcholinesterase inhibited by diisopropylfluorophosphate. J. Appl. Toxicol., 2008, 28, 422-429.